Dr. Reddy's Laboratories received FDA approval for its intravenous vasopressin generic, positioning the company to immediately capture market share in the competitive hospital therapeutics space. This approval allows Dr. Reddy’s to offer a bio-equivalent alternative, creating a new revenue stream within the intensive care segment.